SCICLONE PHARMACEUTICALS INC 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Jun 14, 2017
Insider Transaction Report
Form 4
Zhao Hong
CEO, China Operations
Transactions
- Sale
Common Stock
2017-06-12$10.75/sh−12,500$134,375→ 25,000 total - Exercise/Conversion
Restricted Stock Unit
2017-06-12−12,500→ 185,000 total→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2017-06-12+12,500→ 12,500 total - Exercise/Conversion
Common Stock
2017-06-12+25,000→ 37,500 total - Exercise/Conversion
Common Stock
2017-06-12+3,000→ 40,500 total - Sale
Common Stock
2017-06-12$10.75/sh−3,000$32,250→ 37,500 total - Sale
Common Stock
2017-06-12$10.75/sh−25,000$268,750→ 0 total - Exercise/Conversion
Restricted Stock Unit
2017-06-12−25,000→ 160,000 total→ Common Stock (25,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-06-12−3,000→ 157,000 total→ Common Stock (3,000 underlying)
Footnotes (5)
- [F1]Granted under the Issuer's 2005 Equity Incentive Plan.
- [F2]Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- [F3]Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units will vest on each August 9, 2014, August 9, 2015, August 9, 2016, and August 9, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
- [F4]Provided Reporting Person remains employed by the Issuer, 33.33% of the restricted stock units vested on January 4, 2016, 33.33% will vest on January 3,2017, and 33.34% will vest on January 2, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open.
- [F5]Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.